Tafluprost

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

他氟前列素是一种前列腺素类似物，是氟前列腺素 (FP) 受体 PGF2α 的选择性激动剂。他氟前列素在日常临床实践中对各种类型的青光眼和 OH 患者表现出显着的降眼压作用，且没有任何安全性问题，并且他氟前列素在任何治疗中都非常有效。

Tafluprost, a prostaglandin analog, is the selective agonist of fluoroprostaglandin (FP) receptor PGF2α.Tafluprost showed significant IOP-lowering effects without any safety concerns in patients with various types of glaucoma and OH in daily clinical practice and tafluprost is highly effective in any therapeutic pattern. Tafluprost with reduced BAK has potential as a superior antiglaucoma drug, not only for its IOP-lowering effect but also for its good corneal safety profile. Tafluprost single-use vials treatment was effective in reducing IOP over the 3 years of this study, but visual field performance worsened by 10.3%-13.8% in patients with normal-tension glaucoma.

Cell Viability Assay Cell Line:RGC Concentration:0.1, 1, 3, 10, 100 μM Incubation Time:48 h Result:Enhanced the viability of these cells in a dose-dependent fashion, with an optimal concentration of 3μM.Increased the relative fluorescence intensity (RFI).

Animal Model:Male Sprague rat model Dosage:0.0015% Administration:Via eye drops Result:Increased the number of RGCs and reduced the number of TUNEL-positive cells.Animal Model:Prostaglandin receptor deletion C57BL/6 mice model Dosage:3 μL (0.0015% Tafluprost)Administration:Instillation; Single dose Result:Reduced IOP in WT, EP1KO, EP2KO, EP3KO and FPKO mice, and the average IOP reduction rates were 25.8(2.1)%, 26.3(0.8)%, 24.2(1.4)%, 16.5(1.7)% and 20.9(1.5)%, respectively. (The decrease of IOP in EP3KO and FPKO mice was less than that in WT mice.)

AFP-168,MK2452

GPCR/G Protein

Prostaglandin Receptor

PGF2α

——

——

209860-87-7

452.53

C25H34F2O5

>98% (HPLC)

DMSO:250 mg/mL (552.45 mM)

CC(C)OC(=O)CCC\C=C/C[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1\C=C\C(F)(F)COc1ccccc1

——

(-20℃)

With Ice Pack

≥ 2 years